There could be a breakthrough on the near horizon for African swine fever.
Aptimmune Biologics Inc., a St. Louis, Missouri-based biotechnology company that focuses on developing swine vaccines, has been working on an ASF vaccine for more than a decade — since the moment Aptimmune’s founder, Dr. Federico Zuckermann, realized that he already had the building blocks for a vaccine. Now, Aptimmune is racing against the clock to throw a wrench into ASF spread overseas — and prevent it from reaching U.S. shores. READ MORE